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on peripheral blood progenitor cell (PBPCs) collection after mobilizing therapy in cancer patients. They reported that the absolute number of CD34 + cells strongly correlated with the CD34 + cell and colony-forming units granulocytemacrophage (CFU-GM) yield of the corresponding apheresis product, while the white blood cell (WBC) count on the day of harvest showed only a weak correlation.
In this setting, we would like to describe here our single institution effort aiming to standardize the optimal timing of mobilized CD34
+ cell collection in hematological malignancies.
In our Department, between April 1993 and December 1997, 91 patients with various underlying hematological malignancies (37 multiple myeloma, MM; 27 acute myeloid leukemias, AML; 20 non-Hodgkin's lymphomas, NHL; six Hodgkin disease, HD; one Waldenström disease, WD; one paroxysmal nocturnal hemoglobinuria, PNH) were treated with several types (total cycle number = 130) of chemotherapy (cyclophosphamide 7 g/m 2 ; modified EDAP; DEXA-BEAM; ara-C + mitoxantrone; FLAG; idarubicin + ara-C + etoposide) followed by granulocyte colony-stimulating factor (G-CSF) (n = 114) or granulocytemacrophage colony-stimulating factor (GM-CSF) (n = 16) administration to mobilize CD34 + PBPCs. In one AML, as well as in the PNH patient, only G-CSF was used and the first collection was performed at the sixth day after the starting of growth factor administration. Seventeen patients (nine AML; five MM and three NHL) failed mobilization due to previous heavy pre-treatment or myelodysplastic features in the marrow. Furthermore, five MM patients failed to complete the third cycle of mobilization (DEXA-BEAM), after two effective collections with cyclophosphamide and EDAP, and two MM patients failed at the second cycle (EDAP). A total of 223 leukaphereses (median for each cycle: 1.97; range 1-4) was performed and two blood volumes were processed at a flow rate of 40-80 ml/min. In Table 1 cells/l, WBC/lmonocytes/l at the harvesting day and at the preceding day) and yields of CD34 + PBPCs were determined by simple linear regression analysis and Person's correlation test. As shown in Table 2 and in Figure  1 , only the number of pre-harvest circulating CD34
+ PBPCs was found to represent a highly significant parameter for predicting the quality of single collections, while absolute WBC and monocyte count were not useful in this setting. In addition, linear regression analysis (Figure 2) showed that absolute CD34 + cell number documented just before the first apheresis ('decision point') revealed a strong correlation with the amount of CD34 + PBPCs collected in each cycle.
In conclusion, our data further support the results of Armitage and co-workers 1 and those of several other reports, [2] [3] [4] [5] [6] which emphasize the pivotal role of flow cytometric estimation of CD34 + cell number in predicting optimal timing and yield quality of leukaphereses in hematological malignancies. 
